Oncology Industry
Insights & Trends

April 21, 2020

Kognitic Launches Innovative Map Feature to its Clinical Trial Intelligence Platform

Kognitic announces the launch of an innovative feature to its platform, one which allows its customers to plot the geographic location of active clinical trials into […]
April 21, 2020

Cancer Care in the Time of Covid-19

Cancer Care in the Time of Covid-19 While it seems much of our world has come to a halt since the spread of #covid19 , cancer […]
April 21, 2020

Kognitic Launches Covid-19 Insight Series

With over 1 million globally confirmed Covid-19 cases, the promise of bringing lives back to ‘normal’ seems ambiguous. Amidst several strategies to fight against the disease, […]
April 21, 2020

University of Penn Has Done It Again!

University of #Penn refuses to stop innovating. After having introduced CAR-T to the fight against #cancer, another Penn team has developed an a related technology which […]
April 21, 2020

Don’t Get Blindsided by Emerging Targets

Imalumab is the only drug targeting oxMIF to reach #clinicaltrials, but ultimately was terminated due to poor overall benefit-risk assessment. Now, OncoOne has announced that they […]
April 21, 2020

Tepotinib vs Capmatinib: A Race for Approval

Merck KGaA’s MET inhibitor, Tepotinib, received approval in Japan for #NSCLC yesterday, gaining a lead in the tight race against Capmatinib – Novartis’ MET inhibitor. The […]
April 21, 2020

Celebrating International Day of Women

On International Day of Women in Science. #Kognitic would like to celebrate the great strides which women are making in science. At our company women account […]
April 21, 2020

Take Time for World Cancer Day

Today is World Cancer Day, a day to reflect upon what strides we have been making toward helping the millions of patients battling cancer and focus […]
April 21, 2020

Lynparza Gets NICE’s Stamp of Approval

The National Institute for Health and Care Excellence has recommended #Lynparza for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritonealcancer in adults with […]